Inovio's Voceryq Wins FDA Accelerated Approval for Recurrent Respiratory Papillomatosis, Shares Surge

What happened

INOVIO Pharmaceuticals received FDA accelerated approval for Voceryq (INO-3107) for adults with recurrent respiratory papillomatosis, triggering a premarket surge of over 230%. The approval follows supportive Phase 1/2 data showing an 81.3% reduction in surgical interventions year-over-year, and comes after the first RRP therapy was approved in 2025, making INO a second entrant. This validates the DNA medicine and CELLECTRA electroporation platform, but accelerated approval requires confirmatory trials to verify clinical benefit. The company had been targeting BLA file acceptance by year-end 2025, so the approval appears ahead of schedule and resolves a key binary risk. However, INO's balance sheet remains strained with only about $46.9 million in pro forma cash after a July raise (24.35M at 6/30 plus 22.5M net), implying a need for additional capital to fund launch and confirmatory studies.

Implication

The accelerated approval for Voceryq transforms INO from a pre-approval binary story to a commercial-stage biotech, though still pre-revenue. Confirmation of benefit in the confirmatory trial is mandatory, and INO must execute a launch against an incumbent approved therapy. Financing remains critical; the company likely needs a non-dilutive or less-dilutive capital raise to fund operations and the confirmatory study. Competitive differentiation on durability, surgery reduction, and practicality of the CELLECTRA device will determine long-term uptake. Investors should watch for first sales, confirmatory trial design and enrollment, and any partnership or funding announcements.

Thesis delta

Thesis shifts from NEUTRAL/HOLD to BUY. The primary regulatory overhang is resolved with accelerated approval, validating the platform and asset. However, execution on confirmatory trials, commercialization, and financing remains essential, so a BUY stance is appropriate but with ongoing monitoring.